Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 5/20 | 0.41 |
| ▸ | HRH1 | P35367 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CALCA | P06881 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003021 | 0.95 | MC4R (0.43) | MC4RHRH2HRH1KMT2ACALCA | |
| SCHEMBL12738196 | 0.93 | MC4R (0.52) | MC4RHRH2HRH1KMT2ACALCA | |
| SCHEMBL12737691 | 0.92 | MC4R (0.44) | MC4RHRH2HRH1KMT2AMAPK1 | |
| SCHEMBL14435971 | 0.90 | HRH2 (0.48) | MC4RHRH2HRH1KMT2ACALCA | |
| SCHEMBL12713293 | 0.89 | CALCA (0.46) | KMT2ACALCAMEN1CCR1 | |
| SCHEMBL14431445 | 0.89 | MC4R (0.51) | MC4RHRH2HRH1CALCA | |
| SCHEMBL12738097 | 0.88 | MC4R (0.55) | MC4RHRH2HRH1KMT2AMAPK1 | |
| SCHEMBL14435629 | 0.87 | HRH2 (0.46) | MC4RHRH2HRH1KMT2ACALCA | |
| SCHEMBL14431353 | 0.86 | HRH2 (0.52) | MC4RHRH2HRH1KMT2ACALCA | |
| SCHEMBL14431446 | 0.86 | MC4R (0.49) | MC4RHRH2HRH1KMT2ACALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| WO-2007096186-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | MC4R 1/4885HRH2 1989/4885HRH1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.